The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
== Mechanism of toxicity == Once azinphos-methyl is absorbed it can cause neurotoxic effects, like other organophosphate insecticides. At high concentrations AzM itself can be toxic because it can function as an acetylcholinesterase (AChE) inhibitor. But its toxicity is mainly due to the bioactivation by a cytochrome P450 (CYP450)-mediated desulfuration to its phosphate triester or oxon(gutoxon) (see figure 2). Gutoxon can react with a serine hydroxyl group at the active site of the AChE. The active site is then blocked and AChE is inactivated. Under normal circumstances acetylcholinesterase rapidly and efficiently degrades the neurotransmitter acetylcholine (ACh) and thereby terminates the biological activity of acetylcholine. Inhibition of AChE results in an immediate accumulation of free unbound ACh at the ending of all cholinergic nerves, which leads to overstimulation of the nervous system.
Platelets also promote angiogenesis and tissue regeneration to maintain overall vascular integrity by releasing growth factors like vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Their multifunctional role displays the challenge of innovating synthetic platelets capable of effectively replicating their physiological functions.
== History == The natriuretic effects of progesterone were demonstrated in 1955, and the development of spironolactone as a synthetic antimineralocorticoid analogue of progesterone shortly followed this. Spironolactone was first synthesized in 1957, was patented between 1958 and 1961, and was first marketed, as an antimineralocorticoid, in 1959. Gynecomastia was first reported with spironolactone in 1962, and the antiandrogenic activity of the medication was first described in 1969. This shortly followed the discovery in 1967 that gynecomastia is an important and major side effect of AR antagonists. Spironolactone was first studied in the treatment of hirsutism in women in 1978. It has since become the most widely used antiandrogen for dermatological indications in women in the United States. Spironolactone was first studied as an antiandrogen in transgender women in 1986, and has since become widely adopted for this purpose as well, particularly in the United States where cyproterone acetate is not available. Early oral spironolactone tablets showed poor absorption. The formulation was eventually changed to a micronized formulation with particle sizes of less than 50 μg, which resulted in approximately 4-fold increased potency.
=== 17 May === The Security Service of Ukraine identified and charged six individuals with "illegally disseminating" information about Ukrainian air defences in Kyiv. These individuals took videos of Ukrainian air defences in action then posted them on social media sites such as YouTube. Such information, the SBU alleged, could be used to make Russian strikes more accurate. The penalty for such a charge was five to eight years imprisonment. Russia's defence ministry claimed its forces had destroyed a British-made L-119 howitzer in Ukraine according to a report by state news agency TASS. It also claimed to have struck an ammunition depot in Mykolaiv. The DSM Capella, the last ship to sail under the Black Sea Grain Initiative before its expected expiration on 18 May, left the Ukrainian port of Chornomorsk carrying 30,000 tonnes of corn bound for Turkey. Shortly afterwards, Turkish President Recep Tayyip Erdoğan said that the grain exportation deal between Ukraine and Russia had been extended for two more months. Both Russia and Ukraine welcomed the extension. A child and two others were reported to have been killed and three people were injured after a Russian shell struck outside a shop in Zelenivka, Kherson Oblast. In Donetsk, the city's Russian-backed mayor claimed Ukrainian shelling left five dead and 15 injured.
Sources: en.wikipedia.org
Compared to amorphous structures, semi-crystalline structures lead to a higher stiffness, density, melting temperature and higher resistance of a polymer. Cross-linked polymers: Wide-meshed cross-linked polymers are elastomers and cannot be molten (unlike thermoplastics); heating cross-linked polymers only leads to decomposition. Thermoplastic elastomers, on the other hand, are reversibly "physically crosslinked" and can be molten. Block copolymers in which a hard segment of the polymer has a tendency to crystallize and a soft segment has an amorphous structure are one type of thermoplastic elastomers: the hard segments ensure wide-meshed, physical crosslinking.
In some interpretations of Lindow Man's death, the sinew is a garrotte used to break the victim's neck. However, Robert Connolly, a lecturer in physical anthropology, suggests that the sinew may have been ornamental and that ligature marks may have been caused by the body swelling when submerged. The rib fracture may also have occurred after death, perhaps during the discovery of the body, but is included in some narratives of the Lindow Man's death. The broken neck would have proven the fatal injury, whether caused by the sinew cord tightening around the neck or by blows to the back of the head. After death, Lindow Man was deposited into Lindow Moss face down.
== After Tiselius == By the late 1940s, new electrophoresis methods were beginning to address some of the shortcomings of the Tiselius' moving-boundary electrophoresis, which was not capable of completely separating electrophoretically similar compounds. Rather than charged molecules moving freely through solutions, the new methods used solid or gel matrices in new electrophoresis apparatuses to separate compounds into discrete and stable bands or zones. In 1950, Tiselius dubbed these methods zone electrophoresis. Zone electrophoresis found widespread application in biochemistry after Oliver Smithies introduced starch gel as an electrophoretic substrate in 1955. Starch gel (and later polyacrylamide and other gels) enabled the efficient separation of proteins, making it possible with relatively simple technology to analyze complex protein mixtures and identify minute differences in related proteins. Despite the development of high-resolution zone electrophoresis methods, the accurate control of parameters such as pore size and stability of polyacrylamide gels was still a major challenge in the 20th century. These technical problems were finally solved in the early 2000s with the introduction of a standardized polymerization time for optimized polyacrylamide gels. This enabled, for the first time, to fractionate physiological concentrations of highly purified metal ion cofactors and associated proteins in quantitative amounts for structure analysis.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.